Print ISSN: 2581-5725
Online ISSN: 2456-9267
CODEN : IACHCL
IP Archives of Cytology and Histopathology Research (ACHR) open access, peer-reviewed quarterly journal publishing since 2016 and is published under the Khyati Education and Research Foundation (KERF), is registered as a non-profit society (under the society registration act, 1860), Government of India with the vision of various accredited vocational courses in healthcare, education, paramedical, yoga, publication, teaching and research activity, with the aim of faster and better dissemination of knowledge, we will be publishing the article more...Review Article
Author Details :
Volume : 9, Issue : 2, Year : 2024
Article Page : 67-71
https://doi.org/10.18231/j.achr.2024.015
Abstract
Meningiomas are the most common primary intracranial tumors in adults comprising about one-third of cases. Most of them are slow-growing and follow a benign course. However, some may behave aggressively with recurrence and even metastasis. Histopathological features have long been regarded as the gold standard for diagnosis, grading, and prognostication. Advances in genomics and molecular characteristics of meningiomas have uncovered the potential use of many biomarkers for more accurate grading and prediction of prognosis and recurrence. Precision clinical trials are needed to utilize these biomarkers for targeted therapy. The present review is a snapshot of some of these important updates in meningioma as per the 2021 WHO Classification of Tumors of the Central Nervous System (WHO CNS5).
Keywords: Meningiomas, WHO CNS 5, Molecular markers
How to cite : Chakrabarti I, Mazumder S, WHO CNS 5 and meningiomas: What’s new?. IP Arch Cytol Histopathol Res 2024;9(2):67-71
This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.